Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai Mumbai, 400076, India.
Biocon Biologics Limited, Biocon Park (SEZ), Bommasandra-Jigani Link Road, Bangalore, 560099, India.
Chembiochem. 2022 Dec 5;23(23):e202200489. doi: 10.1002/cbic.202200489. Epub 2022 Nov 10.
The current trend in the biopharmaceutical market has boosted the development and production of biological drugs with high efficacy and fidelity for receptor binding. While high-resolution structural insights into binding epitopes of the receptor are indispensable for better therapeutic design, it is tedious and costly. In this work, we develop a protocol by integrating two well-known NMR-based solution-state methods. Saturation transfer double-difference with methyl-TROSY (STDD-Methyl TROSY NMR) was used to probe methyl binding epitopes of the ligand in a label-free environment. This study was carried out with Human insulin as a model peptide drug, with the insulin growth factor receptor (IGFR), which is an off-target receptor for insulin. Methyl epitopes identified from STDD-Methyl TROSY NMR spectroscopy were validated through the HADDOCK platform to generate a drug-receptor model. Since this method can be applied at natural abundance, it has the potential to screen a large set of peptide-drug interactions for optimum receptor binding. Thus, we propose STDD-Methyl TROSY NMR spectroscopy as a technique for rapid screening of biologics for the development of optimized biopharmaceutics.
当前生物制药市场的趋势推动了具有高效和高受体结合保真度的生物药物的开发和生产。虽然深入了解受体结合表位的高分辨率结构对于更好的治疗设计是必不可少的,但这既繁琐又昂贵。在这项工作中,我们整合了两种著名的基于 NMR 的溶液态方法,开发了一种方案。利用饱和转移双差甲基 TROSY(STDD-Methyl TROSY NMR)在无标记环境中探测配体的甲基结合表位。本研究以人胰岛素作为模型肽药物,以胰岛素生长因子受体(IGFR)作为胰岛素的非靶标受体进行。通过 HADDOCK 平台验证 STDD-Methyl TROSY NMR 光谱中鉴定出的甲基表位,以生成药物-受体模型。由于该方法可以在自然丰度下应用,因此具有筛选大量肽-药物相互作用以获得最佳受体结合的潜力。因此,我们提出 STDD-Methyl TROSY NMR 光谱学作为一种快速筛选生物制剂的技术,用于开发优化的生物药剂学。